Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Sign Of The Times? Micromet’s Stock Price Sluggish Despite Reasons For Optimism

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Biotech well-funded thanks to recent deals and sees blockbuster potential in lymphoma with blinatumomab.

You may also be interested in...



PIPE-Line Gamble Could Let Cadence Sing A Happy Tune

Company aims to file NDAs for pain product and topic anti-infective gel in second quarter.

PIPE-Line Gamble Could Let Cadence Sing A Happy Tune

Company aims to file NDAs for pain product and topic anti-infective gel in second quarter.

Affymax Swings $42 Million Financing To Push Hematide

Private/public infusion will see synthetic ESA through trials and approval.

Table

View full table

Related Content

In Vivo
Pink Sheet
Scrip

Topics

Tags:
BioPharmaceutical
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS067120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By